Roth Capital Reaffirms TG Therapeutics (TGTX) at 'Buy'; Still Sees TGR-1202, TG-1101 as Well Positioned

November 7, 2016 2:51 PM EST
Get Alerts TGTX Hot Sheet
Price: $5.20 +0.97%

Rating Summary:
    8 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade TGTX Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Roth Capital affirms TG Therapeutics (Nasdaq: TGTX) with a Buy/Focus Pick rating and $33 price target following Q3 results and update issued earlier Monday.

Analyst Joseph Pantginis commented today: We believe that the company is well positioned with two of its candidates, TGR-1202 and TG-1101, moving through multiple clinical trials for multiple indications. The structural differences between ‘1202 and other PI3K delta inhibitors seems to be responsible for its differentiated profile that has aroused interest in KOLs not involved in the current study. Part of the interest is peaked from ‘1202 safety profile which may allow its combination with multiple agents including BTK inhibitors, JAK inhibitors, monoclonal antibodies, and chemotherapy, in double or triple combinations. At the upcoming ASH, TGTX will be presenting three oral presentations and three poster presentations, which include ‘1202 studies in combination with other agents. Recently published data indicated that TGR-1202 in combination with Kyprolis targeted c-Myc. As a result of these data the company is looking to utilize '1202 in combination with other agents in order to target c-Myc including combinations with carfilzomib and BET inhibitors. Furthermore, the ability to target c-Myc may allow the company to move use of '1202 into solid tumors such as triple negative breast cancer which is a c-Myc driven tumor.

For an analyst ratings summary and ratings history on TG Therapeutics click here. For more ratings news on TG Therapeutics click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Roth Capital

Add Your Comment